Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | GLA | P06280 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | XDH | P47989 | 1/20 | 0.44 |
| ▸ | ALPL | P05186 | 3/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | ULK1 | O75385 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | ABL1 | P00519 | 2/20 | 0.36 |
| ▸ | SRC | P12931 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.35 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30020861 | 0.81 | CYP1A2 (0.50) | CYP1A2GLAGAAKDM4EXDH | |
| SCHEMBL30020366 | 0.80 | CYP1A2 (0.49) | CYP1A2GLAGAAKDM4EXDH | |
| SCHEMBL17362461 | 0.77 | MAP2K1 (0.48) | — | |
| SCHEMBL27148525 | 0.74 | CYP1A2 (0.49) | CYP1A2GLAGAAKDM4EXDH | |
| SCHEMBL22620744 | 0.72 | CYP1A2 (0.44) | CYP1A2GLAGAAKDM4EXDH | |
| SCHEMBL16008376 | 0.71 | ABL1 (0.46) | CYP1A2GLAGAAKDM4EXDH | |
| SCHEMBL22655542 | 0.71 | KDM4E (0.55) | CYP1A2GAAKDM4EXDHMAPT | |
| SCHEMBL17362895 | 0.70 | CYP1A2 (0.62) | CYP1A2GLAGAAKDM4EXDH | |
| SCHEMBL29849942 | 0.70 | CYP1A2 (0.62) | CYP1A2GLAGAAKDM4EXDH | |
| SCHEMBL15391633 | 0.70 | GAA (0.66) | CYP1A2GLAGAAKDM4EXDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3521289-B1 | MNK INHIBITORS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS INC (US) | 2023-10-25 | — | — | EP | disclosed |
| CN-110183449-B | Mnk inhibitors and methods related thereto | 效应治疗股份有限公司 | 2022-08-19 | — | — | CN | disclosed |
| US-20210338673-A1 | MNK INHIBITORS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS INC (US) | 2021-11-04 | — | — | US | disclosed |
| EP-3521289-A1 | MNK INHIBITORS AND METHODS RELATED THERETO | Effector Therapeutics Inc. (US) | 2019-08-07 | — | — | EP | disclosed |
| US-20190209560-A1 | MNK INHIBITORS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS, INC. | 2019-07-11 | — | — | US | disclosed |
| US-20180085368-A1 | MNK INHIBITORS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS, INC. (NL) | 2018-03-29 | — | — | US | disclosed |
| US-9814718-B2 | MNK inhibitors and methods related thereto | EFFECTOR THERAPEUTICS, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-9814718-B2 | MNK inhibitors and methods related thereto | EFFECTOR THERAPEUTICS, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-9814718-B2 | MNK inhibitors and methods related thereto | EFFECTOR THERAPEUTICS, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-20170266185-A1 | MNK INHIBITORS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS, INC. | 2017-09-21 | — | — | US | disclosed |
| US-20160317536-A1 | MNK INHIBITORS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS, INC. | 2016-11-03 | — | — | US | disclosed |
| US-20160317536-A1 | MNK INHIBITORS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS, INC. | 2016-11-03 | — | — | US | disclosed |
| US-9382248-B2 | Mnk inhibitors and methods related thereto | EFFECTOR THERAPEUTICS, INC. (US) | 2016-07-05 | — | — | US | disclosed |
| US-9382248-B2 | Mnk inhibitors and methods related thereto | EFFECTOR THERAPEUTICS, INC. (US) | 2016-07-05 | — | — | US | disclosed |
| US-9382248-B2 | Mnk inhibitors and methods related thereto | EFFECTOR THERAPEUTICS, INC. (US) | 2016-07-05 | — | — | US | disclosed |
| US-20150376181-A1 | MNK INHIBITORS AND METHODS RELATED THERETO | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2015-12-31 | — | — | US | disclosed |
| US-20150376181-A1 | MNK INHIBITORS AND METHODS RELATED THERETO | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2015-12-31 | — | — | US | disclosed |
| US-20150376181-A1 | MNK INHIBITORS AND METHODS RELATED THERETO | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2015-12-31 | — | — | US | disclosed |
| WO-2015200481-A1 | MNK INHIBITORS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS, INC. (US) | 2015-12-30 | — | — | WO | disclosed |
| WO-2015200481-A1 | MNK INHIBITORS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS, INC. (US) | 2015-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150376181-A1 | MNK INHIBITORS AND METHODS RELATED THERETO | TNNI3K, NIM1K, NEK9 | CYP1A2 3635/4885GLA 3734/4885GAA 1292/4885 |
| US-20160317536-A1 | MNK INHIBITORS AND METHODS RELATED THERETO | TNNI3K, NIM1K, NEK9 | CYP1A2 3635/4885GLA 3734/4885GAA 1292/4885 |
| US-20190209560-A1 | MNK INHIBITORS AND METHODS RELATED THERETO | TNNI3K, NIM1K, NEK9 | CYP1A2 3635/4885GLA 3734/4885GAA 1292/4885 |
| US-20180085368-A1 | MNK INHIBITORS AND METHODS RELATED THERETO | TNNI3K, NIM1K, NEK9 | CYP1A2 3635/4885GLA 3734/4885GAA 1292/4885 |
| US-20210338673-A1 | MNK INHIBITORS AND METHODS RELATED THERETO | TNNI3K, NIM1K, NEK9 | CYP1A2 3635/4885GLA 3734/4885GAA 1292/4885 |
| US-20170266185-A1 | MNK INHIBITORS AND METHODS RELATED THERETO | TNNI3K, NIM1K, NEK9 | CYP1A2 3635/4885GLA 3734/4885GAA 1292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.